Fate Therapeutics (NASDAQ:FATE – Get Free Report) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, risk and profitability.
Risk & Volatility
Fate Therapeutics has a beta of 2.52, meaning that its share price is 152% more volatile than the S&P 500. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500.
Profitability
This table compares Fate Therapeutics and Lakefront Biotherapeutics American Depositary Shares’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Fate Therapeutics | -1,941.09% | -65.08% | -41.73% |
| Lakefront Biotherapeutics American Depositary Shares | N/A | N/A | N/A |
Earnings & Valuation
This table compares Fate Therapeutics and Lakefront Biotherapeutics American Depositary Shares”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Fate Therapeutics | $6.65 million | 32.25 | -$136.32 million | ($1.05) | -1.70 |
| Lakefront Biotherapeutics American Depositary Shares | $1.26 billion | 1.57 | $363.05 million | ($1.41) | -21.21 |
Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Fate Therapeutics. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Fate Therapeutics and Lakefront Biotherapeutics American Depositary Shares, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fate Therapeutics | 1 | 3 | 4 | 0 | 2.38 |
| Lakefront Biotherapeutics American Depositary Shares | 0 | 5 | 3 | 1 | 2.56 |
Fate Therapeutics currently has a consensus target price of $5.90, suggesting a potential upside of 229.61%. Lakefront Biotherapeutics American Depositary Shares has a consensus target price of $37.00, suggesting a potential upside of 23.75%. Given Fate Therapeutics’ higher probable upside, equities research analysts plainly believe Fate Therapeutics is more favorable than Lakefront Biotherapeutics American Depositary Shares.
Institutional & Insider Ownership
97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. 4.7% of Fate Therapeutics shares are held by insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
About Fate Therapeutics
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
About Lakefront Biotherapeutics American Depositary Shares
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
